There are 216 resources available
The future of the tissue agnostic targets
Presenter: Joaquin Mateo
Session: The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies
Resources:
Slides
Webcast
Panel discussion
Presenter: Dario Trapani
Session: The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies
Resources:
Webcast
Wrap-up and roadmap for actions
Presenter: Joaquin Mateo
Session: The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies
Resources:
Slides
Webcast
The regulator perspective on pan-cancer drug development (FDA)
Presenter: Steven Lemery
Session: What are the current roadblocks to histology agnostic biomarker driven approvals?
Resources:
Slides
Webcast
The regulator perspective on biomarker and test development (EMA)
Presenter: Francesco Pignatti
Session: What are the current roadblocks to histology agnostic biomarker driven approvals?
Resources:
Slides
Webcast
The patient perspective on pan-cancer trials and access to drugs
Presenter: Bettina Ryll
Session: What are the current roadblocks to histology agnostic biomarker driven approvals?
Resources:
Slides
Webcast
Design and running of biomarker-driven pan-cancer trials: Methodological perspectives
Presenter: Stefan Michiels
Session: What are the current roadblocks to histology agnostic biomarker driven approvals?
Resources:
Slides
Webcast
Q&A
Presenter: Francesco Pignatti
Session: What are the current roadblocks to histology agnostic biomarker driven approvals?
Resources:
Webcast
Introduction
Presenter: Christoph Benedikt Westphalen
Session: New trial designs, new paths to drug registration
Resources:
Slides
Webcast
Pre-clinical development of targeted agents: Change of mindset from tumour type to mechanism of action
Presenter: Elena Garralda
Session: New trial designs, new paths to drug registration
Resources:
Slides
Webcast